FRANKFURT (Reuters) - Bayer has initiated two new late-stage studies to widen the use of its anti-blood-clotting pill Xarelto, one of its most important new drugs. The German company, which is ...

(AP) Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence of deep ...

Medicare Part D and Medicare Advantage plans with prescription drug coverage may cover Xarelto if it appears on the plan’s formulary. A generic version of Xarelto (rivaroxaban) recently became ...

NEW YORK - U.S. health regulators have again declined to approve proposed wider uses of Bayer AG and Johnson & Johnson's lucrative blood clot preventer Xarelto, the drugmakers said on Friday. The ...

Rivaroxaban, a direct oral anticoagulant (DOAC), demonstrated greater efficacy and similar safety compared with warfarin in patients with chronic kidney disease and atrial fibrillation. Rivaroxaban, a ...

Please provide your email address to receive an email when new articles are posted on . Overall, 1,144 bleeding events occurred by the 1-year follow-up period. There were 577 ischemic stroke or ...

NEW YORK, Feb 14 (Reuters) - U.S. health regulators have again declined to approve proposed wider uses of Bayer AG and Johnson & Johnson's lucrative blood clot preventer Xarelto, the drugmakers said ...

DEAR DR. ROACH: My husband was diagnosed with chronic lymphocytic leukemia (CLL) in 2010 and remained in stage 2 with no effects until 2022. In the interim, he was also diagnosed with atrial ...

Apixaban (Eliquis) was associated with lower serious bleeding rates than rivaroxaban (Xarelto) or warfarin in patients with cirrhosis and atrial fibrillation (AF, Afib) in a nationwide cohort study.